Luca COnia

Dr. Luca COnia

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
NGNICOLA GALEA
NICOLA GALEA
LCLuca COnia
Luca COnia
AAAndrea Ascione
Andrea Ascione
NBNoemi Bruno
Noemi Bruno
FMFabio Miraldi
Fabio Miraldi

LCLuca COnia
Luca COnia
DFDaria Filatova
Daria Filatova
GPGiacomo Carlo Pambianchi
Giacomo Carlo Pambianchi
Livia MarchitelliLivia Marchitelli
Livia Marchitelli
Giulia CundariGiulia Cundari
Giulia Cundari
NGNICOLA GALEA
NICOLA GALEA
Transthyretin cardiac amyloidosis (ATTR-CA) leads to myocardial infiltration, affecting prognosis and survival. Diagnosing early-stage ATTR-CA remains challenging due to its subtle manifestations. This study investigates subclinical myocardial alterations in asymptomatic ATTR mutation carriers (ATTR-MC) using advanced cardiac magnetic resonance (CMR) techniques, including T1 mapping and myocardial strain analysis. A retrospective cohort of 60 subjects was analyzed, comprising 20 ATTR-CA patients, 20 asymptomatic ATTR-MC, and 20 controls. Standard CMR parameters were compared alongside myocardial strain analysis. Results indicated that despite preserved ejection fraction and myocardial morphology, ATTR-MC exhibited significantly impaired left ventricular global longitudinal strain (LV GLS), left atrial reservoir, conduit, and booster pump strain (LA RS, CS, and BPS) compared to controls. However, native T1 and extracellular volume (ECV) values remained within normal ranges, distinguishing early dysfunction from overt amyloid deposition seen in ATTR-CA. These findings suggest that myocardial strain analysis could serve as an early biomarker for subclinical ATTR-CA, offering a potential target for selecting patients who may benefit from early intervention. Implementing CMR-derived strain parameters in clinical practice may improve risk stratification and timely therapeutic decisions in ATTR-MC.